June 24, 2020 -- Critical Path Institute (C-Path) has launched a drug repurposing platform to accelerate the identification of new uses of existing drugs to treat infections, including COVID-19.
C-Path launched the Cure Drug Repurposing Collaboratory to speed up the development of potentially effective drugs for patients with diseases that lack adequate approved treatment options. The goal is to identify drug candidates for future clinical trials and for potential drug labeling in the future.
The program will capture relevant real-world clinical outcome data through the Cure ID platform. Institutions, researchers, private practitioners, government facilities, and healthcare professionals around the world can report novel uses of existing drugs by visiting C-Path's site or downloading the Cure ID mobile app.
The platform was funded with approximately $1.1 million from the U.S. Food and Drug Administration in collaboration with the National Institutes of Health's National Center for Advancing Translational Sciences.